PDCD1 and cancer: Importantly, the binding of PD1-TFc to PDL1 seems not to be affected by protein sialylation, a common alteration of cancer receptors that play a key role in the acquisition of molecular resistance to diagnostic and targeted therapeutic agents (Zhou et al. 2021; Duarte et al. 2021; Rodrigues et al. 2021a, 2021b).